Harvard Bioscience Stock Forecast, Price & News

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

Is Harvard Bioscience a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Harvard Bioscience stock.
View analyst ratings for Harvard Bioscience or view top-rated stocks.

What stocks does MarketBeat like better than Harvard Bioscience?

Wall Street analysts have given Harvard Bioscience a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harvard Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Harvard Bioscience.

How can I listen to Harvard Bioscience's earnings call?

Harvard Bioscience will be holding an earnings conference call on Wednesday, November 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings data on Thursday, August, 5th. The medical instruments supplier reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The medical instruments supplier had revenue of $29.20 million for the quarter, compared to analyst estimates of $27.40 million. Harvard Bioscience had a negative net margin of 2.51% and a positive trailing twelve-month return on equity of 8.03%.
View Harvard Bioscience's earnings history.

How has Harvard Bioscience's stock price been impacted by Coronavirus (COVID-19)?

Harvard Bioscience's stock was trading at $2.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HBIO shares have increased by 189.1% and is now trading at $7.14.
View which stocks have been most impacted by COVID-19.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $114.35 million-$117.42 million, compared to the consensus revenue estimate of $115.29 million.

What price target have analysts set for HBIO?

3 equities research analysts have issued 12 month price objectives for Harvard Bioscience's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Harvard Bioscience's share price to reach $9.00 in the next year. This suggests a possible upside of 26.1% from the stock's current price.
View analysts' price targets for Harvard Bioscience or view top-rated stocks among Wall Street analysts.

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the following people:

• James W. Green, Chairman, President & Chief Executive Officer
• Kenneth F. Olson, COO, Senior VP-Global Operations & Engineering
• Michael A. Rossi, Chief Financial Officer
• Don Stewart, Vice President-North Americas & APAC Sales
• Ryan Wallace, Vice President-Global Sales, Preclinical Systems

Who are some of Harvard Bioscience's key competitors?

Some companies that are related to Harvard Bioscience include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), Charles River Laboratories International (CRL), Bio-Techne (TECH), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of HBIO's competitors.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Hillsdale Investment Management Inc. (0.99%), Strs Ohio (0.24%), Assenagon Asset Management S.A. (0.14%) and Triton Wealth Management PLLC (0.11%). Company insiders that own Harvard Bioscience stock include Alan I Edrick, Bertrand Loy, James W Green, James W Green and Value Fund Lp Palogic.
View institutional ownership trends for Harvard Bioscience.

Which institutional investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., and Strs Ohio.
View insider buying and selling activity for Harvard Bioscience or view top insider-selling stocks.

Which institutional investors are buying Harvard Bioscience stock?

HBIO stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Triton Wealth Management PLLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Alan I Edrick, Bertrand Loy, James W Green, and Value Fund Lp Palogic.
View insider buying and selling activity for Harvard Bioscience or or view top insider-buying stocks.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $7.14.

How much money does Harvard Bioscience make?

Harvard Bioscience has a market capitalization of $291.05 million and generates $102.10 million in revenue each year. The medical instruments supplier earns $-7.81 million in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does Harvard Bioscience have?

Harvard Bioscience employs 444 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is www.harvardbioscience.com.

Where are Harvard Bioscience's headquarters?

Harvard Bioscience is headquartered at 84 OCTOBER HILL RD, HOLLISTON MA, 01746.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at (508) 893-8999 or via email at [email protected].